



Cancer Immunity and Immunotherapy

Tuesday, June 20, 2023
Boston Marriott Copley Place
Boston, Massachusetts

Course Directors:

Asha Pillai, MD, Regeneron Therapeutics
Jennifer Guerriero, PhD, Brigham & Women's Hospital

Organized in collaboration with



Society for Immunotherapy of Cancer

FOCiS[®]
Federation of Clinical
Immunology Societies www.focisnet.org

Agenda



7:30-8:00 AM	Continental Breakfast
8:00-8:45 AM	Principles of Tumor Immunity – Abul Abbas, MD, University of California, San Francisco
8:45-9:30 AM	The Tumor Microenvironment – Matthew Spitzer, PhD, University of California, San Francisco
9:30-10:15 AM	B Cells – Tullia Bruno, PhD, University of Pittsburgh
10:15-10:30 AM	Coffee Break
10:30-11:15 AM	T Cell Exhaustion – Mary Philip, MD, PhD, Vanderbilt University Medical Center
11:15 AM-12:00 PM	Immune-Mediated Toxicities – Alexandra-Chloe Villani, PhD, Massachusetts General Hospital
12:00-12:45 PM	Lunch
12:45-1:30 PM	Shiny New CARs – Joshua Brody, MD, Mount Sinai
1:30-2:15 PM	Tumor Vaccines – Catherine Wu, MD, Dana Farber Cancer Institute
2:15-2:30 PM	Coffee Break
2:30-3:15 PM	Innovations with NK Cells – Rizwan Romee, MD, Dana Farber Cancer Institute
3:15-4:00 PM	Combinatorial Therapeutics in Solid Tumors – Israel Lowy, MD, PhD, Regeneron
4:00-4:15 PM	Break
4:15-5:00 PM	Challenges 1: Real-Time Analyses of Tumor Immunotherapy Evasion – Shashank Patel, PhD, Immunai Corp
5:00-5:45 PM	Challenges 2: Quantitative Analysis of CAR-T Cell Pharmacology and Response – Daniel Kirouac, PhD, Notch Therapeutics

Learning Objectives

At the conclusion of this course, attendees will be able to:

- Describe mechanisms of the immune response against cancer cells and how these responses are regulated during cancer development and progression.
- Describe the principles underlying chimeric antigen receptor-transduced T cells (CAR-T cells) and T cell receptor (TCR)-transduced T cells and their efficacy in the treatment of leukemias and other cancers.
- Appreciate the potential opportunities and limitations of utilizing CAR-T cells for treating solid tumors and understand the development of second generation CARs.
- Understand the biology of immune checkpoint pathways and checkpoint blockade therapy for solid tumors, the development of biomarkers to predict therapeutic responses, and the potential for combination therapies.
- Describe the unique adverse event profile associated with immune checkpoint blockade and CAR-T cell therapy, and clinical strategies for managing those immune-related toxicities.
- Understand the potential of emerging strategies for cancer immunotherapy, including innate immune therapeutics and bispecific targeting approaches.

Faculty Disclosures

FOCIS requires resolution of all faculty conflicts of interest to ensure CME activities are free of commercial bias. The following faculty members have indicated that they have no relationship which, in the context of their presentation(s), could be perceived as a potential conflict of interest.

- | | |
|----------------------|---------------------------|
| • Abul Abbas | • Shashank Patel |
| • Joshua Brody | • Mary Philip |
| • Tullia Bruno | • Rizwan Romee |
| • Jennifer Guerriero | • Alexandra-Chloe Villani |
| • Daniel Kirouac | • Catherine Wu |

The following presenters have indicated a relationship in which the context of their presentations could be perceived by some as a real or apparent conflict of interest, but do not consider that it will influence their presentations. If a presenter is not listed, he or she had no relationship to disclose. The number following each company name represents the specific relationship from the key below.

Key: 1 – Consultant / Advisor; 2 – Employee; 3 – Lecture Fees; 4 – Equity / Owner; 5 – Patents/Royalty; 6 – Grant Support

- Israel Lowy – Regeneron Therapeutics²
- Asha Pillai – Regeneron Therapeutics²
- Matthew Spitzer – Teiko.bio^{1, 4}; Fluidigm³; Genentech/Roche⁶

Course Directors



Asha Pillai, MD
Regeneron Therapeutics



Jennifer Guerriero, PhD
Brigham & Women's Hospital

Speakers



Abul Abbas, MD
University of California,
San Francisco



Joshua Brody, MD
Mount Sinai



Tullia Bruno, PhD
University of Pittsburgh



Daniel Kirouac, PhD
Notch Therapeutics



Israel Lowy, MD, PhD
Regeneron Therapeutics



Shashank Patel, PhD
Immunai Corp



Mary Philip, MD, PhD
Vanderbilt University
Medical Center



Rizwan Romee, MD
Harvard University



Matthew Spitzer, PhD
University of California
San Francisco



Alexandra-Chloe Villani, PhD
Massachusetts
General Hospital



Catherine Wu, MD
Dana Farber Cancer
Research Institute

CME Information

In the past, FOCIS has made it possible for participants to obtain CME credit for attending the educational courses. In order to enable all those involved in the research and treatment of immune-mediated diseases to participate in the exchange of ideas that contribute to the forward motion of the field, FOCIS will not offer CME credit for any course or session at the FOCIS annual meeting. Certificates of attendance will be available upon request after completion of the course evaluations and post-test.

SAVE THE DATE

June 18-21



ANNUAL MEETING

San Francisco
CALIFORNIA

SAVE THE DATE!



**ADVANCED COURSE IN BASIC
& CLINICAL IMMUNOLOGY**

FEBRUARY 4-7, 2024 | ESTANCIA LA JOLLA | SAN DIEGO, CALIFORNIA